Mini-tablet

Efficiently Identifying the Optimal API Form

Our proprietary technology has been successfully applied to over 1,500 drug molecules. By designing precise crystallization conditions tailored to your target compound's physicochemical properties, we identify the most optimal solid form for development.

Speed & Efficiency

Preclinical Screening

For new candidate compounds, our goal is to find the thermodynamically most stable crystal form quickly and efficiently.

Structural Prediction

Through structural analysis and property testing, we predict salt or co-crystal formation sites to guide targeted screening.

Resource Optimization

We deliver results with less material consumption, fewer experiments, and shorter timelines through precision-designed experiments.

Targeted Strategy

Deploying polymorph, salt, and co-crystal screening strategies based on specific early-stage development needs.

Comprehensive Protection

Late-Stage & IP Screening

When an innovative drug enters Phase II or III, comprehensive patent protection is critical for long-term success.

Systematic IP Screening

We identify all possible crystal forms—especially metastable forms—suitable for industrial development to secure your intellectual property.

Tiered Methodology

Relying on experience across hundreds of IP projects, we utilize tiered strategies to ensure thorough coverage.

Enabling Crystallization

We utilize enabling crystallization methods to discover and protect forms that traditional methods might miss.

Related Platforms of Crystal Pharmatech

Absolute Structure Determination



Crystallization Process Development



Solid Form Screening



Related Resources

News

Crystal Pharmatech Launches OEB4/OEB5 High-Potency Laboratory, Expanding Global CDMO Capabilities for Complex Drug Development

02 Apr 2026



Technical Article

Bilayer Gastroretentive Modified-Release Tablets: A Quality-by-Design Approach to Achieving Precise Drug Release and Prolonged Gastric Retention

01 Apr 2026



News

Patients can’t carry a fridge around: research meets the real world

20 Mar 2026



Small Molecule

First-Time-Right 3-STEP Approach Developability Assessment API Form and Solid-State Research Crystallization Development Services Pre-formulation Studies Analytical Research and Quality Control Formulation Development Clinical and Commercial GMP Manufacturing Clinical Supply

Crystal Bio Solutions

Biologics Characterization and CMC Analytics Bioanalytical and Biomarker Services Quantitative Clinical Pharmacology (QCP)

Crystal NAX

DNA Synthesis RNA Synthesis LNP Formulation Services Analytical & Characterization Services Early-Phase Manufacturing Catalogue Products

Platforms

Solid Form Screening Solid Form Developability Evaluation Absolute Structure Determination Crystallization Process Development Conventional Oral Solid Dosage Forms Bioavailability Enhancement for Insoluble Compounds & PROTAC & Oral Peptides Mini-tablet

Quick Links

Highlights News Events Knowledge Hub Webinar Series

 bd_global@crystalpharmatech.com  (925) 558-5040



U.S
NJ Sites: Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey, USA 08512

2005 Eastpark Blvd, Cranbury, New Jersey, USA 08512

CA Site: 7133 Koll Center Parkway, Suite 200, Pleasanton, California, USA 94566

Canada
6800 Kitimat Rd, Unit 1, Mississauga, Ontario, Canada L5N 5M1

China
No. 288, Jiangyun Road, Suzhou Industrial Park, Suzhou, China 215123

Floor 1, Bldg. 3, 68 Chunpu Road, Suzhou Industrial Park, Suzhou, China 215123

Subscribe to be the first to get the updates!

Sitemap